EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells

By means of an unbiased, automated fluorescence microscopy-based screen, we identified the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib as potent enhancers of the differentiation of HL-60 acute myeloid leukemia (AML) cells exposed to suboptimal concentrations of vitamin A (all-trans retinoic acid, ATRA) or vitamin D (1α,25-hydroxycholecalciferol, VD). Erlotinib and gefitinib alone did not promote differentiation, yet stimulated the acquisition of morphological and biochemical maturation markers (including the expression of CD11b and CD14 as well as increased NADPH oxidase activity) when combined with either ATRA or VD. Moreover, the combination of erlotinib and ATRA or VD synergistically induced all the processes that are normally linked to terminal hematopoietic differentiation, namely, a delayed proliferation arrest in the G₀/G₁ phase of the cell cycle, cellular senescence, and apoptosis. Erlotinib potently inhibited the (auto)phosphorylation of mitogen-activated protein kinase 14 (MAPK14, best known as p38^MAPK) and SRC family kinases (SFKs). If combined with the administration of ATRA or VD, the inhibition of p38^MAPK or SFKs with specific pharmacological agents mimicked the pro-differentiation activity of erlotinib. These data were obtained with 2 distinct AML cell lines (HL-60 and MOLM-13 cells) and could be confirmed on primary leukemic blasts isolated from the circulation of AML patients. Altogether, these findings point to a new regimen for the treatment of AML, in which naturally occurring pro-differentiation agents (ATRA or VD) may be combined with EGFR inhibitors.     

ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform

ERCC1 (excision repair cross-complementation group 1) plays essential roles in the removal of DNA intrastrand crosslinks by nucleotide excision repair, and that of DNA interstrand crosslinks by the Fanconi anemia (FA) pathway and homology-directed repair processes (HDR). The function of ERCC1 thus impacts on the DNA damage response (DDR), particularly in anticancer therapy when DNA damaging agents are employed. ERCC1 expression has been proposed as a predictive biomarker of the response to platinum-based therapy. However, the assessment of ERCC1 expression in clinical samples is complicated by the existence of 4 functionally distinct protein isoforms, which differently impact on DDR. Here, we explored the functional competence of each ERCC1 protein isoform and obtained evidence that the 202 isoform is the sole one endowed with ERCC1 activity in DNA repair pathways. The ERCC1 isoform 202 interacts with RPA, XPA, and XPF, and XPF stability requires expression of the ERCC1 202 isoform (but none of the 3 others). ERCC1-deficient non-small cell lung cancer cells show abnormal mitosis, a phenotype reminiscent of the FA phenotype that can be rescued by isoform 202 only. Finally, we could not observe any dominant-negative interaction between ERCC1 isoforms. These data suggest that the selective assessment of the ERCC1 isoform 202 in clinical samples should accurately reflect the DDR-related activity of the gene and hence constitute a useful biomarker for customizing anticancer therapies.     

THE EFFECTS OF INJURY PREVENTION WARM-UP PROGRAMMES ON KNEE STRENGTH IN MALE SOCCER PLAYERS

The study investigates the effects of the 11+ and HarmoKnee injury prevention programmes on knee strength in male soccer players. Under-21-year-old players (n=36) were divided equally into: the 11+, HarmoKnee and control groups. The programmes were performed for 24 sessions (20-25 min each). The hamstrings and quadriceps strength were measured bilaterally at 60°·s^-1, 180°·s^-1 and 300°·s^-1. The concentric quadriceps peak torque (PT) of the 11+ increased by 27.7% at 300°·s^-1 in the dominant leg (p<0.05). The concentric quadriceps PT of HarmoKnee increased by 36.6%, 36.2% and 28% in the dominant leg, and by 31.3%, 31.7% and 20.05% at 60°·s^-1, 180°·s^-1 and 300°·s^-1 in the non-dominant leg respectively. In the 11+ group the concentric hamstring PT increased by 22%, 21.4% and 22.1% at 60°·s^-1, 180°·s^-1 and 300°·s^-1, respectively in the dominant leg, and by 22.3%, and 15.7% at 60°·s^-1 and 180°·s^-1, in the non-dominant leg. In the HarmoKnee group the hamstrings in the dominant leg showed an increase in PT by 32.5%, 31.3% and 14.3% at 60°·s^-1, 180°·s^-1 and 300°·s^-1, and in the non-dominant leg hamstrings PT increased by 21.1% and 19.3% at 60°·s^-1 and 180°·s^-1 respectively. The concentric hamstrings strength was significantly different between the 11+ and control groups in the dominant (p=0.01) and non-dominant legs (p=0.02). The HarmoKnee programme enhanced the concentric strength of quadriceps. The 11+ and HarmoKnee programmes are useful warm-up protocols for improving concentric hamstring strength in young professional male soccer players. The 11+ programme is more advantageous for its greater concentric hamstring strength improvement compared to the HarmoKnee programme.     

Common and divergent functions of Beclin 1 and Beclin 2

In a recent paper published in Cell, He and colleagues reported the identification and functional characterization of Beclin 2, a mammal-specific homolog of the evolutionarily conserved autophagy-regulatory and oncosuppressive factor Beclin 1. In spite of a non-negligible degree of sequence identity, Beclin 1 and Beclin 2 differ from each other in multiple aspects, including their functional profile as well as the genomic organization of the respective loci.Originally identified as a BCL-2-interacting partner capable of protecting mice from viral encephalitis¹, Beclin 1 — the mammalian ortholog of yeast Atg6 — is nowadays well known as a core component of the class III phosphoinosite-3-kinase (PI3K) enzymatic complex that initiates the formation of autophagosomes in the course of macroautophagy (hereafter referred to as autophagy)². Presumably owing to the critical function of autophagy in embryonic development, mice lacking both copies of the Beclin 1-coding gene (Becn1) die early during embryogenesis. Moreover, Becn1^+/− mice suffer from a high incidence of spontaneous tumors, indicating that Beclin 1 acts as a haploinsufficient tumor suppressor³. At least in part, this reflects the central role that autophagy plays in the maintenance of intracellular homeostasis. Indeed, baseline levels of autophagy mediate the removal of various cytoplasmic entities that might favor oncogenesis, including damaged mitochondria and protein aggregates⁴. Conversely, established neoplasms often harness the cytoprotective functions of autophagy to their own benefit². The pathophysiological relevance of autophagy is not limited to cancer, but extends to a large panel of human diseases, including neurodegenerative, cardiovascular and infectious conditions⁵. Thus, during the last decade autophagy-regulatory signaling pathways have been intensively investigated.Until now, Beclin 1 was considered as the only Beclin encoded by the mammalian genome, sharing some degree of structural homology with so-called “BH3-only” proteins, pro-apoptotic members of the BCL-2 family that are involved in the activation of cell death in response to stress⁶. In a recent paper published in Cell, the research group led by Beth Levine⁷ identified a human and a mouse protein sharing 57% and 44% sequence identity with human and mouse Beclin 1, respectively, de facto unveiling the existence of an additional, mammal-specific ortholog of Atg6, Beclin 2. The mouse Beclin 2 mRNA was detected in multiple organs including the brain, skeletal muscle, placenta, thymus and uterus, as was the human protein in both fetal and adult brain tissues. These data demonstrate that the current classification of mouse and human Beclin 2-encoding genes (i.e., {"type":"entrez-nucleotide","attrs":{"text":"NG_022940","term_id":"298676453","term_text":"NG_022940"}}NG_022940 and {"type":"entrez-nucleotide","attrs":{"text":"NG_028451","term_id":"331028236","term_text":"NG_028451"}}NG_028451) as pseudogenes is incorrect.The knockdown of Beclin 2 reduced several manifestations of basal or starvation-induced autophagy in cultured mammalian cells, including the degradation of the autophagic substrate p62, the aggregation of a fluorescent form of LC3 into cytoplasmic dots and the lipidation of endogenous LC3. All such effects, which were not due to an increased autophagosomal turnover (as verified in the presence of the lysosomal inhibitor bafilomycin A1), could be rescued upon the transgene-driven expression of a non-interferable Beclin 2 variant. Thus, similar to Beclin 1, Beclin 2 regulates autophagy⁷. In fact, Beclin 2 turned out to physically interact with several (but not all) components of the class III PI3K complex organized around Beclin 1, including the catalytic subunit VPS34 as well as the regulatory factors ATG14, AMBRA1 and UVRAG, but not RUBICON (Figure 1A). Beclin 2 also appeared to share with Beclin 1 the ability to bind BCL-2, although only the latter gets dissociated from such an interaction in the course of stress-induced autophagy^7,8. As the greatest divergence between mammalian Beclins involves their N terminus, He and colleagues employed the N-terminal domain of Beclin 2 as a bait in a yeast two-hybrid screen, and identified G protein-coupled receptor (GPCR)-associated sorting protein 1 (GASP1) as a Beclin 2-specific interactor. Thus, similar to GASP1 (but not to Beclin 1), Beclin 2 was required for the agonist-induced lysosomal degradation of a subset of GPCRs including opioid receptor δ1 (DOR) and cannabinoid receptor 1 (CB1R). Importantly, such an activity, but not the capacity of Beclin 2 to regulate autophagic responses, appears to rely on the physical interaction between Beclin 2 and GASP1.Open in a separate windowFigure 1Common and divergent functions of mammalian Beclins. Specificity of the main interactors (A) and functions (B) ascribed to mammalian Beclin 1 and Beclin 2 to date. GPCR, G protein-coupled receptor; RTK, receptor tyrosine kinase.To obtain insights into the physiological functions of Beclin 2, He and colleagues attempted to generate Becn2^−/− mice, finding that these animals survived embryonic and early post-natal development at sub-Mendelian rates (approximately 4%). Not only Becn2^+/− and Becn2^−/− mouse embryonic fibroblasts, but also the brain of Becn2^+/− animals exhibited significant autophagic defects, corroborating the role of Beclin 2 in the regulation of autophagy in vivo. Moreover, these genotypes were associated with increased basal levels of multiple GPCRs, including CB1R and dopamine receptor D2 (DRD2)⁷. In line with the notion that increased CB1R signaling accrues food intake and hence favors obesity and insulin resistance, while pharmacological or genetic CB1R inhibition has opposite effects⁹, Becn2^+/− mice accumulated more weight than their wild-type littermates in response to a standard (as well as to a high-fat) diet. At odds with their Becn1^+/− counterparts, Becn2^+/− mice also exhibited impaired glucose tolerance and decreased insulin sensitivity, two effects that could be reverted by a chemical CB1R antagonist⁷. Taken together, these data demonstrate that besides regulating autophagy, Beclin 2 plays a unique role in glucose metabolism.Beclin 1 is known to regulate various processes other than autophagy, including vacuolar protein sorting and the degradation of specific growth factor receptors¹⁰. Thus, in spite of 44% - 57% sequence identity, the two mammalian Beclins described to date are relatively different from each other, exhibiting functional profiles that overlap to a limited degree (Figure 1B). Interestingly, He and colleagues have previously shown that defects in stimulus-induced autophagy (including those introduced by the Becn1^+/− genotype) are coupled to decreased endurance and altered glucose metabolism during acute exercise, as well as with an impaired capacity of training to protect mice against diet-induced glucose intolerance⁸. Part of these phenomena were shown to reflect defects in the AMP-activated protein kinase (AMPK)-dependent exposure of glucose transporters on the plasma membrane of skeletal muscle cells. It is therefore tempting to speculate that the metabolic phenotype of Becn2^+/− may in part originate from peripheral defects in glucose handling linked to autophagy. Thus, although the force driving the divergence of mammalian Beclins remains to be elucidated, it may reflect the need for an integrated regulation of central and peripheral mechanisms of metabolic homeostasis. Further studies are required to address this hypothesis.     

Mitochondrial membrane permeabilization by HIV-1 Vpr

The mitochondrion is a privileged target for apoptosis-modulatory proteins of viral origin. Thus, viral protein R (Vpr) can target mitochondria and induce apoptosis via a specific interaction with the permeability transition pore complex (PTPC). Vpr cooperates with the adenine nucleotide translocator (ANT) to form large conductance channels and to trigger all the hallmarks of mitochondrial membrane permeabilization (MMP). The Vpr/ANT interaction is direct, since it is abolished by the addition of a peptide corresponding to the Vpr binding site of ANT, ADP, ATP, or by Bcl-2. Accordingly, Vpr modulates MMP through direct structural and functional interactions with PTPC proteins.     

The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway

Previous biochemical studies suggested that HIV-1-encoded Vpr may kill cells through an effect on the adenine nucleotide translocase (ANT), thereby causing mitochondrial membrane permeabilization (MMP). Here, we show that Vpr fails to activate caspases in conditions in which it induces cell killing. The knock-out of essential caspase-activators (Apaf-1 or caspase-9) or the knock-out of a mitochondrial caspase-independent death effector (AIF) does not abolish Vpr-mediated killing. In contrast, the cytotoxic effects of Vpr are reduced by transfection-enforced overexpression of two MMP-inhibitors, namely the endogenous protein Bcl-2 or the cytomegalovirus-encoded ANT-targeted protein vMIA. Vpr, which can elicit MMP through a direct effect on mitochondria, and HIV-1-Env, which causes MMP through an indirect pathway, exhibit additive (but not synergic) cytotoxic effects. In conclusion, it appears that Vpr induces apoptosis through a caspase-independent mitochondrial pathway.     

Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo

Atractyloside (Atr) binds to the adenine nucleotide translocator (ANT) and inhibits ANT-mediated ATP/ADP exchange on the inner mitochondrial membrane. In addition, Atr can trigger opening of a non-specific ion channel, within the ANT-containing permeability transition pore complex (PTPC), which is subject to redox regulation and inhibited by cyclosporin A (CsA). Here we show that the cytotoxic effects of Atr, both in vivo and in vitro, are determined by its capacity to induce PTPC opening and consequent mitochondrial membrane permeabilization (MMP). Thus, the Atr-induced MMP and death of cultured liver cells are both inhibited by CsA as well as by glutathione (GSH) and enhanced by GSH depletion. Similarly, the hepatorenal toxicity of Atr, assessed in vivo, was reduced by treating mice with CsA or a diet rich in sulfur amino acids, a regime which enhances mitochondrial GSH levels. Atr injection induced MMP in hepatocytes and proximal renal tubular cells, and MMP was reduced by either CsA or GSH. Acetaminophen (paracetamol)-induced acute poisoning was also attenuated by CsA and GSH, both in vitro and in vivo. Altogether these data indicate that PTPC-mediated MMP may determine the hepatorenal toxicity of xenobiotics in vivo.